San Diego-based Viking Therapeutics marked alone as a significant competitor from the weight loss drug market place in February just after revealing promising facts from the mid-stage trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented being a weekly injection and in March the company